ReviewDiscover oncology2026
Machine learning applications in the detection and treatment of esophageal cancer.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Esophageal cancer (EC) is a gastrointestinal malignancy associated with a poor prognosis worldwide. It is characterized by an insidious onset, marked tumor heterogeneity, and complex diagnostic and therapeutic pathways. Consequently, clinical management continues to face challenges in early screening, accurate diagnosis, and the assessment of treatment response and prognosis. In recent years, the rapid advancement of artificial intelligence (AI) and machine learning (ML) techniques in medical image analysis and multidimensional data modeling has provided novel technological approaches for the precision diagnosis and treatment of EC. This narrative review summarizes recent advances in the application of AI in EC, with a particular focus on endoscopic and imaging-assisted diagnosis, prediction of treatment response and prognostic assessment. Existing studies have reported promising diagnostic performance of deep learning-based endoscopic image analysis models. In some controlled or retrospective settings, their performance has approached that of expert readers in the detection of EC and precancerous lesions, although prospective validation remains limited. ML models integrating clinical information, radiomic features, and selected biomarkers have also shown promising performance in predicting treatment response and supporting risk stratification. However, most existing studies are based on retrospective, single-center, or regionally confined datasets and are subject to several limitations, including population heterogeneity, insufficient data standardization, limited external validation, and poor model interpretability, which collectively hinder clinical translation. Overall, AI holds great promise for the precision management of EC; however, its clinical translation still depends on multicenter collaboration, the establishment of high-quality datasets, prospective validation studies, and the parallel development of ethical and regulatory frameworks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.